Critical Control Announces Private Placement and Plan of Arrangement

/EINPresswire.com/ — CALGARY, ALBERTA–(Marketwired – May 11, 2017) – Critical Control Energy Services Corp. („Critical Control” or the „Corporation”) (TSX:CCZ) announces that it intends to complete a non-brokered private placement of units (the „Units”) consisting of a newly created class of Series A Preferred Shares (the „Preferred Shares”) and common share purchase warrants (the „Warrants”) for gross proceeds of a minimum of $3,000,000 to a maximum of $5,000,000 (the „Offering”). Contemporaneously with the Offering, the Corporation intends on issuing $4,650,000 of Preferred Shares to the current common shareholders of the Corporation in exchange for some or all of their existing common shares (the „Arrangement”).

„The completion of the Offering will immediately improve the Corporation’s balance sheet, liquidity and cash flow,” said Alykhan Mamdani, President and CEO of Critical Control. „In management’s opinion, the creation of the Preferred Share combined with both the Offering and the Arrangement improves the Corporation’s capital structure by providing greater long term flexibility to finance growth.”

The Corporation currently has no shares outstanding other than common shares. The Preferred Shares underlying the Offering and the Arrangement will have a $2.00 deemed value and a maximum of 4,825,000 Preferred Shares will be distributed pursuant to the Offering and the Arrangement. The Preferred Shares will entitle the holders to an 8% cumulative dividend paid quarterly, will be redeemable by the Corporation after 5 years from initial issuance, and the cumulative dividend rate shall be reset after the 5-year anniversary to be the Canada 5-year bond rate plus 5%, with a minimum rate of 8%.

The Offering

The Offering will be for a minimum of 1,500,000 and a maximum of 2,500,000 Units at $2.00 per Unit. Each unit shall consist of one Preferred Share with a $2.00 deemed value and one Warrant to acquire one common share of the Corporation for $0.20 per common share. Each Warrant shall expire 2 years from the date on which it is issued.

Any closing of subscriptions for the Offering (the „Closing”) is subject to the subscription of a minimum of 1.5 million units for minimum proceeds of $3.0 million. The Closing will also be subject to the completion of the Arrangement and the approval of the Toronto Stock Exchange to list the Preferred Shares on the Toronto Stock Exchange.

Management and Directors of the Corporation are expected to subscribe for 375,000 Units, for total gross proceeds of $750,000. Closing is expected to occur with the Arrangement on or about June 30, 2017.

The Offering is expected to be non-brokered and shall be completed upon reliance on exemptions from the prospectus requirements of applicable securities regulations. Subscribers to the Units shall have statutorily imposed hold periods attributed to the Preferred Shares acquired thereunder and to the common shares acquired from the issuance of the Warrants. The Offering may be subject to a finder’s fee.

Proceeds of the Offering will be used to reduce the Corporation’s bank debt.

The Arrangement

The Arrangement will allow existing holders of common shares of the Corporation to exchange any portion of their common shares for Preferred Shares on the basis of one Preferred Share for every 12.9 common shares they tender for conversion. This exchange ratio is based upon a conversion rate of $2.00 per Preferred Share and a price of $0.155 per common share, representing a premium of 14.8% over the closing price of the common shares on the Toronto Stock Exchange on May 11, 2017.

Under the Arrangement, holders of common shares will not be required to exchange their common shares under the Arrangement and may elect to keep some or all of their common shares. A maximum of 29,992,500 common shares will be exchanged for a maximum of 2,325,000 Preferred Shares under the Arrangement. In the event holders of common shares in aggregate elect to receive more than 2,325,000 Preferred Shares, the maximum number of Preferred Shares shall be distributed to them on a pari passu basis based upon their election. In the event the holders of common shares in aggregate elect to receive less than 2,325,000 Preferred Shares, the remaining Preferred Shares will be distributed pro rata to those holders of common shares who do not make a valid election subject to a maximum of 2,325,000 Preferred Shares being distributed pursuant to the Arrangement and in accordance with the aforementioned exchange ratio.

Details of the Arrangement will be distributed to the holders of the common shares in an information circular associated with the Corporation’s Annual and Special Meeting to be held in Calgary on June 29, 2017 (the „Meeting”). The Arrangement is expected to be completed on or about June 30, 2017 through a statutory plan of arrangement under section 193 of the Business Corporation Act (Alberta), which will be subject to court approval and approval of the shareholders of the Corporation at the Meeting. In addition, the Arrangement will also be contingent upon the Corporation reaching the minimum Offering.

About Critical Control

Critical Control provides solutions for the collection, control and analysis of measurement and operational data related to oil and gas wells across North America. We provide services to capture the data, cloud-based software to visualize and manage it and the business intelligence to make quicker and more informed operational decisions.

Forward-Looking Information

This press release contains „forward-looking information” within the meaning of Canadian securities legislation. Forward-looking information generally refers to disclosure about an issuer’s business, capital, or operations that is prospective in nature, and includes future-oriented financial information about the issuer’s prospective financial performance or financial position.

The forward-looking information in this press release relates to the proposed terms and anticipated benefits of the Arrangement and the Offering. No assurance can be given that the Arrangement or the Offering will close on these terms or that the Arrangement and the Offering will close at all. Actual results could differ materially from those anticipated in this press release due to prevailing economic conditions, failure to obtain the requisite regulatory and security holders approvals, and other factors, many of which are beyond the control of the Corporation.

The Corporation assumes no obligation to update or revise the forward-looking information in this press release, unless it is required to do so under Canadian securities legislation.

Lee, Hill & Johnston Insurors Earns Agency of the Year Award

(L to R) John Benson, Chairman of the Board & CEO of Frankenmuth Insurance; John Lee of Lee, Hill & Johnston Insurors; Pratt Hill of Lee, Hill & Johnston Insurors; and Fred Edmond, President & COO

We are so pleased to present this award to the agency and its staff and look forward to many decades of continued partnership with Lee, Hill & Johnston. — Frankenmuth Insurance President and COO Fred Edmond

Frankenmuth Insurance named Lee, Hill & Johnston Insurors as its 2016 “Agency of the Year.” The award is presented to one agency that is the top performer in profitability, growth and policy retention.

Lee, Hill & Johnston Insurors, located in Statesboro, Georgia, has also been named a “Preferred Plus” Partner for 2017. This prestigious distinction is awarded to the top 5 percent of all 550 independent agencies representing the insurance company. This is the third year the agency has been recognized as a Preferred partner.

“2017 marks the 13th year Lee, Hill & Johnston Insurors has been a valued partner of Frankenmuth Insurance,” says Frankenmuth Insurance President and COO Fred Edmond. “We are so pleased to present this award to the agency and its staff and look forward to many decades of continued partnership with Lee, Hill & Johnston.”

Lee, Hill & Johnston Insurors has been appointed with Frankenmuth Insurance since 2004.

Share article on social media or email:

Redwood Asset Management Announces Change of Fund Name

/EINPresswire.com/ — TORONTO, ON–(Marketwired – May 11, 2017) – Redwood Asset Management Inc. („Redwood”) is pleased to announce that the Redwood Floating Rate Preferred Fund has been renamed as the Redwood Canadian Preferred Share Fund („the Fund”), effectively immediately.

The Fund is available with two different mutual fund purchase options, as well as an ETF that trades on the Aequitas NEO Exchange Inc. („NEO”) exchange under the symbol RPS.

„When we launched this mandate almost two years ago, the ‚floating rate’ concept was consistent with our view of the market environment,” said Peter Shippen, President and Chief Executive Officer of Redwood Asset Management. „Given the active nature of this portfolio and our desire to manage money without constraints, we believe that this new name will better reflect a broader focus for the strategy, and its ability to invest across the preferred share market.”

Clients will see the new name reflected on client statements on May 16, 2017. As a result of the renaming of the Fund, the ETF units will see a change in CUSIP; there are no changes to the FundServ codes.

Redwood Canadian Preferred Share Fund will continue to employ an active, fundamental approach to investing in preferred shares to provide a high-quality source of tax-efficient income. „We are very proud of the Fund’s strong track record, and believe it continues to represent an attractive alternative to other areas of the fixed-income market,” said Mr. Shippen.

Redwood Canadian Preferred Share Fund (formerly Redwood Floating Rate Preferred Fund)

The Redwood Canadian Preferred Share Fund aims to provide a consistent stream of income with potential for capital appreciation by investing in Canadian income producing securities and Canadian equities.

Information on the fund can be found at https://www.redwoodasset.com or by speaking with your investment advisor.

About Redwood Asset Management
Redwood Asset Management is a Toronto-based investment fund manager, focused on delivering unique investment solutions managed by boutique global investment managers to Canadian investors. Redwood Asset Management is a wholly owned subsidiary of Purpose Investments Inc., which has over $3.3 billion in assets under management. More information about Redwood’s product offerings is available at www.redwoodasset.com.

The Redwood Floating Rate Preferred Fund changed its name and its investment strategy on May 26, 2015 to invest primarily in floating rate preferred shares.

Commissions, trailing commissions, management fees and expenses all may be associated with investment funds. Investment funds are not guaranteed, their values change frequently and past performance may not be repeated. Please read the prospectus before investing.

Global Operating Room Equipment and Supplies Market Analysis and Forecast 2022 by Size, Share and Growth Rate

According to Stratistics MRC, the Global Operating Room Equipment & Supplies Market accounted for $24.5 billion in 2015 and is expected to reach $32.1 million by 2022 growing at a CAGR of 3.9%. Increasing patient preference for minimally invasive surgeries and Rising geriatric population coupled with growing number of surgeries are the factors driving the market growth. Unfavourable Healthcare Reforms in the U.S is restraining the market.

Browse the report: http://www.orbisresearch.com/reports/index/operating-room-equipment-and-supplies-global-market-outlook-2015-2022

Anesthesia Machines is expected to be the largest segment in equipment type in terms of market revenue. Hospitals accounted for the largest market revenue and ambulatory surgery centers segment is expected to grow at the highest CAGR during the forecast period. Surgical Instruments is expected to be the largest market revenue and accessories segment is expected to grow at the highest CAGR. North America is expected to be the largest market revenue followed by Europe. However Asia-Pacific is expected to grow at the highest compound annual growth rate during the forecast period.

Some of the key players in the market include Philips Healthcare, Getinge Group, Medtronic, Inc., Berchtold Corporation, Steris Corporation, GE Healthcare, Stryker Corporation, Dragerwerk AG & Co. KGAA, Hill-Rom Holdings, Inc., Siemens Healthcare GmbH, Karl Storz GmbH & Co. Kg, Mizuho SOI, Creative Health Tech Pvt. Ltd., Trumpf Medical and ValleyLab.

Request a sample of the report: http://www.orbisresearch.com/contacts/request-sample/184622

Equipment Type Covered:
Surgical Imaging Devices
Mini C-Arms
Mobile C-Arms
Multi-Parameter Patient Monitors
Operating Tables
General Operating Tables
Specialty Operating Tables
Anesthesia Machines
Operating Lights
Halogen Lights
LED Lights
Electrosurgical Units

Supplies Type Covered:
Surgical Instruments
Accessories
Disposable Materials
Other Operating Room (OR) Supplies
Circuits
Safety products
Kidney trays
Table pads
Procedure trays & packs
Battery handles

End Users Covered:
Hospitals
Outpatient Facilities
Ambulatory Surgery Centers

Regions Covered:
North America
US
Canada
Mexico
Europe
Germany
France
Italy
UK
Spain
Rest of Europe
Asia Pacific
Japan
China
India
Australia
New Zealand
Rest of Asia Pacific
Rest of the World
Middle East
Brazil
Argentina
South Africa
Egypt

What our report offers:
– Market share assessments for the regional and country level segments
– Market share analysis of the top industry players
– Strategic recommendations for the new entrants
– Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets
– Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
– Strategic recommendations in key business segments based on the market estimations
– Competitive landscaping mapping the key common trends
– Company profiling with detailed strategies, financials, and recent developments
– Supply chain trends mapping the latest technological advancements

About Us:

Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Information:

Hector Costello
Senior Manager – Client Engagements
4144N Central Expressway,
Suite 600, Dallas,
Texas – 75204, U.S.A.
Phone No.: +1 (214) 884-6817; +9164101019
Email: sales@orbisresearch.com

Colorado Springs Company, Pyxant Labs Inc. Adds 25 Jobs

News Image

Pyxant Labs has added 12 full-time staff at its Colorado Springs site and 13 additional people at other US locations. These recent personnel additions follow facility improvements, laboratory equipment additions, and IT systems enhancements during 2016. These people bring our total employment to 53 people, further building our best-in-the-industry team.

Our medication management clinical toxicology services now provide 24-hour turnaround time for most Colorado clinics and hospitals. We assess 85 drugs and metabolites, such as opioids, antidepressants, and drugs of abuse, among others.

We will offer less-than-48-hour turnaround for perinatal umbilical cord toxicology testing starting in July 2017. This clinical toxicology assay supports physician diagnoses of opioid withdrawal and other drug dependencies in newborn babies. Treatment of drug dependence in newborns is more effective and safer when a doctor can confirm the particular source of drug dependency, fast following birth. This service includes same-day local courier pickup and delivery of specimens from Colorado hospitals. Our turnaround time is the fastest in the industry; doctors commonly wait three weeks to receive this test result.

“The experience Pyxant Labs has gained in the past 17 years serving the highly stringent pharmaceutical industry has been instrumental in building a best-in-class Clinical Laboratory Services division. From the onset, Pyxant Labs CLS has one the most qualified and efficient LC/MS/MS method development teams in the entire industry. Furthermore, the extensive experience Pyxant Labs has gained working in the highly regulated drug development environment, which includes five FDA and numerous pharmaceutical company inspections, makes Pyxant Labs CLS one of the laboratories that observes the most rigorous regulatory operations and the laboratory of choice to send your specialty samples to. The clinical industry, especially the medication management sector, needs a high quality laboratory like Pyxant Labs,” said Jean Pineault, President and COO.

“Our business requires people with extensive scientific education, specialized training, and experience in chemistry, biology, toxicology, and clinical healthcare. Attracting the right people is of course crucial to fast growth, especially considering our science, quality, and regulatory performance paradigms. I particularly appreciate the support of the Colorado Springs Chamber and EDC, who supported attracting key people with unique skills from the East Coast to relocate to Colorado Springs and join Pyxant Labs,” said Maurice Gaubatz, Founder and CEO.

About Pyxant Labs – Pyxant Labs Inc. is a privately held bioanalytical laboratory, operating two business units:

Pyxant Labs Contract Research Organization (CRO) provides bioanalytical support for FDA-regulated pharmaceutical development trials. Studies produce blood and tissue samples, which we assay in our analytical chemistry laboratory to determine how much of a new drug is in a subject at a particular point in time. Such evaluations support safety and efficacy studies of new pharmaceuticals, an essential requirement for FDA approval.

Pyxant Labs Clinical Laboratory Services (CLS) is a fast-growing clinical toxicology business unit serving medical providers, other laboratories, and hospitals. We daily receive and assay urine, oral fluid, and tissue specimens for more than 85 drugs, including opioids, psychiatric drugs, cardiac meds, and street drugs. Our fast assay results provide insight for medical practitioners to improve patient outcomes through better management of medications.

For more information, contact Kathy Bouard at 719-593-1165 or kbouard(at)pyxant(dot)com – http://www.pyxant.com

Share article on social media or email:

Author Michael Gearrin’s New Book „Dawgs” Is an Affectionate Chronicle of the Dogs Whose Antics, Personalities, and Love Indelibly Touched the Life of One Family

News Image

Michael Gearrin, a former paramedic with a career spanning thirty-five years, has completed his new book “Dawgs”: a poignant memorial to the six unforgettable Jack Russell Terriers whose adventurous spirits left permanent impressions on the hearts of their family members.

Published by New York City-based Page Publishing, Michael Gearrin’s affectionate memoir brings a lovingly boisterous procession of terriers to life and reminds us of the profound impact dogs have on the lives of those who love them.

Readers who wish to experience this heartwarming work can purchase “Dawgs” at bookstores everywhere, or online at the Apple iTunes store, Amazon, Google Play or Barnes and Noble.

For additional information or media inquiries, contact Page Publishing at 866-315-2708.

About Page Publishing:

Page Publishing is a traditional New York-based full-service publishing house that handles all the intricacies involved in publishing its authors’ books, including distribution in the world’s largest retail outlets and royalty generation. Page Publishing knows that authors need to be free to create – not bogged down with complicated business issues like eBook conversion, establishing wholesale accounts, insurance, shipping, taxes and the like. Its roster of authors can leave behind these tedious, complex and time-consuming issues, and focus on their passion: writing and creating. Learn more at http://www.pagepublishing.com.

Share article on social media or email:

Women’s Excellence Now Offers New Comprehensive Weight Management Program

News Image

Women’s Excellence has a comprehensive weight management program to help patients achieve their weight loss goals and maintain a healthy lifestyle. Women’s Excellence will develop a strategic plan to help patients successfully lose weight and keep it off.

The first step to the program is an initial evaluation and physical exam. Next, patients will receive a comprehensive set of labs to measure hormone levels and metabolism.

Throughout the program, patients will work one-on-one with a Weight Management Specialists to document goals, expected results, and to determine a vitamin and supplement regimen.

If you are a woman who is looking for a customized weight management program, call Women’s Excellence today for an appointment to begin your wellness journey. Women’s Excellence offices are conveniently located in Birmingham, Lake Orion, and Clarkston.

Women’s Excellence is the most comprehensive obstetric and gynecologic office in Michigan. Additionally, they specialize in menopause, weight control, bladder control, endometriosis, robotic surgery and midwifery services. Women’s Excellence is committed to staying at the forefront of innovation with cutting edge technologies utilizing robotic surgery and minimally invasive surgical options when possible. The knowledgeable and compassionate physicians and healthcare providers of Women’s Excellence focus on patient-centered processes to deliver the highest quality of care. They are affiliated with most insurances. They offer seamless medical record access via a state of the art patient portal and use the latest technology for record keeping and sharing, making the patient experience easier and more efficient. Women’s Excellence is taking new patients and is conveniently located in three locations throughout southeastern Michigan, Birmingham, Lake Orion, and Clarkston. For more information, visit http://www.womensexcellence.com.

Keywords: Diet plan, Natural weight loss programs, comprehensive weight loss programs, diet pills and supplements, fast and effective weight loss, weight loss tips, weight management products, diet and exercise plan for weight loss, how to get more energy, how to be more active with family and friends, disease prevention, illness prevention, best weight loss plan for 2017

Share article on social media or email:

Global Diabetic Retinopathy Treatment Market Primary Research, Risk Analysis, Product Research, Trends and Forecast by 2022

According to Stratistics MRC, the Global Diabetic Retinopathy Treatment market is expected to reach $10.24 billion by 2022. Rising prevalence of diabetics, increasing management financial support, change in lifestyle and global aging population are the factors driving the market growth. However, Lack of accurate diagnosis, a lack of skilled ophthalmologist coupled with poor infrastructure and extended approval time for drugs are hampering the growth of global diabetic retinopathy market. Increase in awareness of diabetic retinopathy treatment and improvement of patient monitoring are some of the major trends in the market. The two main stages of diabetic retinopathy are non-proliferated and proliferated. Proliferated diabetic retinopathy is the mainly insecure stage and has the risk of detachment into the vitreous leading to severe vision loss.

Browse the report: http://www.orbisresearch.com/reports/index/diabetic-retinopathy-treatment-global-market-outlook-2015-2022

North America leads the global diabetic retinopathy market due to vast number of aging population. The Asia Pacific diabetic retinopathy market is expected to witness profitable growth over the estimated period due to the occurrence of unmet needs in the developing countries such as China and India. These countries are expected to be the fastest growing diabetic retinopathy markets in Asia-Pacific region.

Some of the key players in the market include Regeneron Pharmaceuticals Inc., ThromboGenics, Genentech, Bayer Healthcare, Alimera Sciences, Actavis PLC, BCN Peptides, Novartis AG, Ampio Pharmaceuticals, Kowa Group, Sirnaomics Incorporation, Abbott Laboratories Ltd, Glycadia Pharmaceuticals, Alcon Laboratories Inc. and Parexel International Corp.

Request a sample of the report: http://www.orbisresearch.com/contacts/request-sample/184621

Type of Treatments Covered:
Intraocular Steroid Injection
Vitrectomy
Anti-Vascular Endothelial Growth Factor (VEGF) drug
Laser Surgery

Disease Type Covered:
Proliferative Diabetic Retinopathy (PDR)
Non-Proliferative Diabetic Retinopathy (NPDR)
Moderate
Mild
Severe

End Users Covered:
Ophthalmic Clinics
Ambulatory Surgical Centers
Hospitals
Other End Users

Regions Covered:
North America
US
Canada
Mexico
Europe
Germany
France
Italy
UK
Spain
Rest of Europe
Asia Pacific
Japan
China
India
Australia
New Zealand
Rest of Asia Pacific
Rest of the World
Middle East
Brazil
Argentina
South Africa
Egypt

What our report offers:
– Market share assessments for the regional and country level segments
– Market share analysis of the top industry players
– Strategic recommendations for the new entrants
– Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets
– Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
– Strategic recommendations in key business segments based on the market estimations
– Competitive landscaping mapping the key common trends
– Company profiling with detailed strategies, financials, and recent developments
– Supply chain trends mapping the latest technological advancements

About Us:

Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Information:

Hector Costello
Senior Manager – Client Engagements
4144N Central Expressway,
Suite 600, Dallas,
Texas – 75204, U.S.A.
Phone No.: +1 (214) 884-6817; +9164101019
Email: sales@orbisresearch.com

Author Jeffery J. Horacek, O.D.’s Newly Released “Renew My Heart, O God: Daily Devotions for Healing Your Heart” is a Devout Year-long Study Offering Hope and Renewal

News Image

“Renew My Heart, O God: Daily Devotions for Healing Your Heart”: 366 days of devotions and meditation specifically chosen to offer comfort, peace, and hope. “Renew My Heart, O God: Daily Devotions for Healing Your Heart” is the creation of published author Jeffery J. Horacek, a practicing optometrist, avid student of the Bible, and former Bible study teacher.

“It is my prayer that you will find God within these pages and that you will cultivate a new desire to pray consistently and to read God’s Word. It is reading His Word and being in His presence that will transform your life and renew the wounded heart within you. It’s time to exchange your sorrow and pain for His comfort and peace, your guilt and shame for His assurance and forgiveness, and your turmoil and despair for His hope and joy. Ezekiel 36:26a says, ‘I will give you a new heart and put a new spirit in you;’—it’s time to come and enter in—God’s waiting for you inside.” -Jeffery J. Horacek, O.D.

Published by Christian Faith Publishing, Jeffery J. Horacek’s new book is an inspiring daily guide to healing and the renewal of the heart and soul.

View a synopsis of “Renew My Heart, O God: Daily Devotions for Healing Your Heart” on YouTube.

Readers can purchase “Renew My Heart, O God: Daily Devotions for Healing Your Heart” at traditional brick and mortar bookstores, or online at Amazon.com, Apple iTunes store, Kobo, or Barnes and Noble.

For additional information or inquiries about “Renew My Heart, O God: Daily Devotions for Healing Your Heart,” contact the Christian Faith Publishing media department at 866-554-0919.

Share article on social media or email:

LALATRENDS.COM Cuts Out the Middle (Wo)Man and Brings the Best Lingerie Designs Direct From Designers and Factories to Consumers’ Door Step

LA LA Trends

I, along with our group of investors, wanted to disrupt the online lingerie shopping sphere, by offering our customers the best lingerie styles – from everyday to sexy – direct from production factories and essentially cutting out the middle person

http://www.LaLatrends.com – a new online marketplace for quality lingerie brings the best lingerie designs – direct from designers and lingerie factories – to customer’s doorsteps. Based in Downtown Los Angeles, LALATRENDS has just launched online.

LALATRENDS features a large selection of lingerie, bras, panties, and hosiery for every woman – regardless of size and shape. Prices range from $4.95 – $69.95. From Babydolls and Teddys to bra sets, thongs, briefs, panty hose, thigh highs, and leggings, http://www.lalatrends.com offers more than 300 styles and free shipping on orders over $25. To celebrate the launch, LALATRENDS is offering 20% off plus Free Shipping on bras and bra sets using the promo code: BraSale.

LALATRENDS sales and marketing is lead by Christopher Palumbo, former head of Online Sales at Fredrick’s of Hollywood. “I, along with our group of investors, wanted to disrupt the online lingerie shopping sphere, by offering our customers the best lingerie styles – from everyday to sexy – direct from production factories and essentially cutting out the proverbial, “Middle (Wo)man.”

Stand out styles include:

  • Bengal Bodysuit ($14.95) – one piece leopard print bodysuit with cutout sides and adjustable straps
  • Luxurious Satin Robe ($19.95) – satin robe with ¾ sleeves and sash front tie
  • Natalie Gown ($19.95) – two piece black lace halter dress with lace up details and thong
  • Christine Chemise ($19.95) – satin chemise with black lace cups
  • Lydia Cami Set ($24.95) – double strap satin cami with delicate black lace cups. Comes with matching satin shorts with black lace inserts
  • Candy Bra Set ($19.95) – two piece padded bra with underwire cups and lace trim. Comes with matching thong
  • Silvia Panties ($4.95) – lace V cut, low rise panties

LALATRENDS.com is poised to become every woman’s go-to shopping site for all types of lingerie styles at the best prices. Featuring products sourced directly from the industry’s best production factories, LALATRENDS features top quality fabrics, the latest design trends, very competitive prices, and the highest customer service to ensure happy women receive lingerie they will love wearing.

Share article on social media or email: